The research interests of Chen Wang, Ph.D., lie in developing and applying bioinformatics and computational tools to make disease-related discoveries and facilitate next-generation sequencing-based translational applications. From a bioinformatics perspective, Dr. Wang has been mainly working on sequencing-based variant callings and pathway integrative analysis to identify aberrant changes in diseases.
With close interactions with basic science and clinical investigators, Dr. Wang also has long-term research interests in gynecological cancers, especially ovarian cancer, with an emphasis in identification of molecular and genetic signatures relevant to prognosis and therapeutic options.
- Sequencing-based structural variation detections
- Discovery and validation of molecular subtypes in gynecological cancer
- Integrative analysis to identify dysregulated pathways in diseases
Significance to patient care
Dr. Wang's bioinformatics efforts in structural change detections have led to several research projects and clinical applications using tools he has developed, including a sequencing-based noninvasive prenatal fetal test.
With his interest in ovarian cancer, Dr. Wang also aims to validate, understand and test clinical utilities of molecular signatures that he previously discovered for predicting prognosis and facilitating treatment decisions.
- Senior member, IEEE, 2015-present
- Funding recipient, The Eric and Wendy Schmidt Fund for AI Research and Innovation, 2023.